In 2004, newspaper headlines read “Major Pharmaceutical Firm Concealed Drug Information” after New York Attorney General Eliot Spitzer alleged that GlaxoSmithKline, PLC (GSK) engaged in misleading and fraudulent conduct with respect to its antidepressant Paxil. Mr. Spitzer claimed GSK misled consumers and healthcare providers by disseminating only information on its positive clinical trials, despite GSK’s disclosure of the results of all of its pediatric trials to the Food and Drug Administration (FDA) and presentation of the available results of its negative and inconclusive studies at medical conventions. Three months after the suit was filed, GSK settled with the New York Attorney General. The company agreed to pay $2.5 million and to disclose information from all clinical trials conducted after 2000 through a clinical trial registry, which GSK had developed before it reached the settlement.

Download the .PDF to learn more!